Cell line · CVCL_1167
Papers51
1 to 20 of 51
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| 18β-Glycyrrhetinic Acid Exerts Subgroup-Specific Antitumor Activity and Enhances Radiosensitivity in Medulloblastoma. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The MALAT1-EZH2 axis regulates PRC2 activity and promotes the mesenchymal phenotype in pediatric atypical teratoid/rhabdoid tumors. | J Neurooncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| 7,7"-dimethoxyagastisflavone induced MYCN/MYBL2-dependent apoptosis and metabolism reprogramming in Sonic Hedgehog medulloblastoma. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Detection of structural DNA variants in medulloblastomas using optical genome mapping. | Acta Neuropathol Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exploring the prognostic molecular mechanisms of medulloblastoma through methylation-transcriptome integration. | SAGE Open Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GPC6 facilitates progression of SHH-subgroup medulloblastoma by enhancing Hedgehog secretion and signaling responses. | J Biomed Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Recombinant Monoclonal Antibodies for Detecting the Tubulin Post-Translational Modifications Glutamylation and Lysine-40 Acetylation. | Cytoskeleton (Hoboken) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The dual HDAC/PI3K inhibitor CUDC-907 inhibits the growth and proliferation of MYC-driven Group 3 medulloblastoma. | Cell Death Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors. | Genome Biol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks. | Oncogene | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Identification and validation of a metabolism-related gene signature for predicting the prognosis of paediatric medulloblastoma. | Sci Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. | Mol Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Neurodegeneration-associated protein VAPB regulates proliferation in medulloblastoma. | Sci Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Design, synthesis, and biological investigation of selective human carbonic anhydrase II, IX, and XII inhibitors using 7-aryl/heteroaryl triazolopyrimidines bearing a sulfanilamide scaffold. | J Enzyme Inhib Med Chem | 2023 | Its Methods give the RRID and name the line | PubMed | |
| CYP19A1 mediates severe SARS-CoV-2 disease outcome in males. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1167/papers